Acute Pulmonary Embolism. Pulmonary heart disease and diseases of pulmonary circulation
Conditions
Interventions
Intervention 1: Intervention: in this group patients will be received 1.5 million Units venous streptokinase, infused during 2 hours. Before treatment starting, Echocardiography and CT- angiography ac
Treatment - Drugs
Intervention: in this group patients will be received 1.5 million Units venous streptokinase, infused during 2 hours. Before treatment starting, Echocardiography and CT- angiography achieve for all pa
In control group, 250,000 Units bolus Streptokinase infuse during 30minutes and then 100,000 Units per hour infuse during 24 hours.
Sponsors
Vice Chancellor for research,Tehran Heart Center (TUMS)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria:streptokinase only begin for massive or submassive pulmonary emboli patients who have these conditions: unstable hemodynamic (systolic blood pressure less than 90 mmHg or reduce systolic blood pressure more 40 mmhg) intermediate or sever RV dysfunction(right ventricle) Exclusion criteria: history of hemorrhagic stroke or unknown origin stroke;Ischemic stroke in past 6 months;central nervous system neoplasm; major trauma,head surgery or injury in past 3 months;TIA attack in past 6 months;oral anticoagulant drugs users;pregnancy or 1st post partum week;traumatic resuscitation;resistant hypertension(systolic blood pressure more than180 mmHg);progressive liver disease;infected endocarditis;active stomach ulcer;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary artery pressure(PAP). Timepoint: before begining of streptokinase and 24-72h after treatment begining. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Yaser Jenab
Tehran Heart Center
Outcome results
None listed